AbbVie Inc (NYSE:ABBV) reported that it will showcase new data assessing MAVYRET™, its once-daily, ribavirin-free therapy for people with chronic hepatitis C virus infection across all key genotypes (GT1-6), at the yearly meeting of the AASLD.
Sixteen company scientific abstracts have been approved, including two oral presentations evaluating the application of MAVYRET in patients across genotypes with compensated cirrhosis and treatment-naïve subjects with genotype 3 HCV. These patients have historically had limited treatment alternatives. A third oral presentation assesses adherence to cure with MAVYRET in the clinical development plan. The Liver Meeting® 2017 is scheduled to take place from October 20 to October 24, 2017.
Janet Hammond, M.D., Ph.D., the VP of Infectious Diseases Development at AbbVie, expressed that the company’s data presentations at The Liver Meeting 2017 reinforce their commitment to patients with hepatitis C. These data add to a strong collection of clinical study data to further improve scientific knowledge of MAVYRET’s efficacy and safety across a number of patient populations.
Researchers will also showcase data received from the MAVYRET clinical program assessing patients with metabolic, renal and cardiovascular conditions and data on HCV patient preferences.
Fred Poordad, M.D. expressed that on the back of AASLD’s newly introduced HCV treatment guidance, they are thrilled to witness additional data on MAVYRET across a broad range of subjects. The updated recommendations on accessible treatments, including the application of MAVYRET in the majority of people, serve as an additional source of data to assist physicians make treatment decisions.
In the last trading session, the stock price of AbbVie declined 0.35% to close the day at $91.42. The decline came at a share volume of 4.82 million compared to average share volume of 7.93 million. After the recent decline, the market cap of firm was seen at around $146 billion.